These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8138659)
1. MCA serum determination in breast carcinoma patients for the diagnosis of bone metastases. Dominguez-Gadea L; Martin-Curto LM; Crespo A; Avila C Int J Biol Markers; 1993; 8(4):203-7. PubMed ID: 8138659 [TBL] [Abstract][Full Text] [Related]
2. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
3. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. Zissimopoulos A; Petrakis G; Stellos K; Baziotis N Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400 [TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
5. Simple method for comparing reliability of two serum tumour markers in breast carcinoma. O'Brien DP; Gough DB; Skehill R; Grimes H; Given HF J Clin Pathol; 1994 Feb; 47(2):134-7. PubMed ID: 8132827 [TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of mucin-like associated antigen (MCA) in neoplasms of the mammary gland]. Kopczyński Z; Stachowicz A; Kociałkowski K; Grodecka-Gazdecka S Ginekol Pol; 1993 Feb; 64(2):87-92. PubMed ID: 8359732 [TBL] [Abstract][Full Text] [Related]
7. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Steger GG; Mader R; Derfler K; Moser K; Dittrich C Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251 [TBL] [Abstract][Full Text] [Related]
8. MCA performance in preoperative breast cancer patients. Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the new tumor marker MCA in the follow-up of patients with mammary carcinoma. Müller-Brand J; Mäcke H Int J Biol Markers; 1993; 8(2):130-2. PubMed ID: 8366296 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of mucinous carcinoma-associated antigen (MCA) tests in breast carcinomas. Günes I; Miserez AR; Müller-Brand J; Maecke H Int J Biol Markers; 1992; 7(4):222-4. PubMed ID: 1491177 [TBL] [Abstract][Full Text] [Related]
12. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites. De Wit R; Hoek FJ; Bakker PJ; Veenhof CH J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
15. MCA in patients with breast cancer: correlation with CEA and CA15-3. Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta AM Int J Biol Markers; 1990; 5(1):14-21. PubMed ID: 2230347 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888 [TBL] [Abstract][Full Text] [Related]
17. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan? Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321 [TBL] [Abstract][Full Text] [Related]
18. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. Crippa F; Bombardieri E; Seregni E; Castellani MR; Gasparini M; Maffioli L; Pizzichetta M; Buraggi GL J Nucl Biol Med (1991); 1992; 36(1):52-5. PubMed ID: 1450226 [TBL] [Abstract][Full Text] [Related]
19. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer. Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068 [TBL] [Abstract][Full Text] [Related]
20. Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring. Molina R; Jo J; Filella X; Zanon G; Grau JJ; Joseph J; Bedini JL; Biete A; Ballesta AM Int J Biol Markers; 1993; 8(2):113-23. PubMed ID: 8366294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]